1. Home
  2. AMH vs IONS Comparison

AMH vs IONS Comparison

Compare AMH & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Homes 4 Rent of Beneficial Interest

AMH

American Homes 4 Rent of Beneficial Interest

HOLD

Current Price

$29.52

Market Cap

11.3B

Sector

Real Estate

ML Signal

HOLD

Logo Ionis Pharmaceuticals Inc.

IONS

Ionis Pharmaceuticals Inc.

HOLD

Current Price

$83.15

Market Cap

13.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMH
IONS
Founded
2012
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.3B
13.5B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
AMH
IONS
Price
$29.52
$83.15
Analyst Decision
Buy
Strong Buy
Analyst Count
17
22
Target Price
$37.29
$84.09
AVG Volume (30 Days)
3.5M
1.7M
Earning Date
01-01-0001
04-11-2026
Dividend Yield
4.28%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.70
Revenue
N/A
N/A
Revenue This Year
$5.07
$29.86
Revenue Next Year
$4.32
$0.53
P/E Ratio
$26.59
$118.79
Revenue Growth
N/A
N/A
52 Week Low
$28.85
$23.95
52 Week High
$39.49
$86.74

Technical Indicators

Market Signals
Indicator
AMH
IONS
Relative Strength Index (RSI) 46.79 52.49
Support Level $31.16 $80.39
Resistance Level $32.03 $84.96
Average True Range (ATR) 0.72 2.45
MACD -0.00 -0.28
Stochastic Oscillator 47.19 44.11

Price Performance

Historical Comparison
AMH
IONS

About AMH American Homes 4 Rent of Beneficial Interest

American Homes 4 Rent is a real estate investment trust focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's geographical markets include Dallas, Texas; Indianapolis, Indiana; Atlanta, Georgia; and Charlotte, North Carolina in terms of the number of properties in each.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Share on Social Networks: